Ferlay J, Ervik M, Lam F, LaveRCanne M, Colombet M, Mery L et al (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today Accessed 24 Apr 2024
Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C et al (2013) Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 37(3):219–225
Chalasani V, Chin JL, Izawa JI (2009) Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 3:S193–S198
PubMed Central PubMed Google Scholar
Rice KR, Koch MO, Kao CS, Pedrosa JA, Kaimakliotis HZ, MasteRCon TA et al (2015) Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology. Urol Oncol 33(20):e23–e29
Abd El-Latif A, Watts KE, Elson P, Fergany A, Hansel DE (2013) The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy. J Urol 189:1263–1267
Weizer AZ, Wasco MJ, Wang R, Daignault S, Lee CT, Shah RB (2009) Multiple adverse histological features increase the odds of under staging T1 bladder cancer [published correction appears in J Urol. 2009 Sep;182(3):1237]. J Urol 182(1):59–65
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M et al (2020) EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol 77(2):223–250
Pons F, Orsola A, Morote J, Bellmunt J (2011) Variant forms of bladder cancer: basic considerations on treatment approaches. Curr Oncol Rep 13(3):216–221
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (2016) The 2016 WHO Classification of TumouRC of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular TumouRC. Eur Urol 70(1):93–105
EAU Guidelines (2025) Edn. presented at the EAU annual congress Madrid
Deuker M, Martin T, Stolzenbach F, Rosiello G, Collà Ruvolo C, Nocera L et al (2021) Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. Clin Genitourin Cancer 19(1):60-68.e1
DuRCun F, Elshabrawy A, Wang H, Wu S, Liss MA, Kaushik D et al (2022Jun) Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy. Urol Oncol 40(6):275.e1-275.e10
Pyrgidis N, Sokolakis I, Haltmair G, Hatzichristodoulou G (2023) The perioperative and long-term outcomes of patients with variant histology bladder cancer undergoing radical cystectomy: A propensity score-matched analysis with pure urothelial carcinoma. Actas Urol Esp (Engl Ed) 47(10):645–653. English, Spanish
Ramos P, Mateus A, Manso M, Botelho F, Silva A, Silva J et al (2024) Prognostic impact of variant histology in bladder cancer: would early and aggressive treatment shift the paradigm? Urol Oncol 42(5):161.e1-161.e8
Lin HY, Ye H, Kernen KM, Hafron JM, Krauss DJ (2018) National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging. Cancer Med 7(11):5370–5381
PubMed Central CAS PubMed Google Scholar
Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S et al (2017) Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodal Bladder-sparing Therapy. Eur Urol 72(1):54–60
Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A et al (2023) Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol 84(4):381–389
Alfred Witjes J, Max Bruins H, Carrión A, Cathomas R, Compérat E, Efstathiou JA et al (2024) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol 85(1):17–31
Kouba E, Cheng L (2016) Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization classification: molecular and clinical characteristics. Endocr Pathol 27(3):188–199. https://doi.org/10.1007/s12022-016-9444-5
Jung K, Ghatalia P, Litwin S, Horwitz EM, Uzzo RG, Greenberg RE et al (2017) Small-cell carcinoma of the bladder: 20-year single-institution retrospective review. Clin Genitourin Cancer 15(3):e337–e343. https://doi.org/10.1016/j.clgc.2016.09.005
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA et al (2014) Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol 32(6):826–832. https://doi.org/10.1016/j.urolonc.2014.01.020
Article PubMed Central PubMed Google Scholar
Lopez-Beltran A, Requena MJ, Montironi R, Blanca A, Cheng L (2009) Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol 40(7):1023–1028. https://doi.org/10.1016/j.humpath.2009.01.001
Minato A, Noguchi H, Tomisaki I, Fukuda A, Kubo T, Nakayama T et al (2018) Clinical significance of squamous differentiation in urothelial carcinoma of the bladder. Cancer Control 25(1):1073274818800269. https://doi.org/10.1177/1073274818800269
Article PubMed Central PubMed Google Scholar
Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL et al (1997) Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15(3):1022–1029. https://doi.org/10.1200/JCO.1997.15.3.1022
Comments (0)